ARID1A and neoplasm: Protective features included PR positivity (>10 %), preserved E-cadherin, and smaller tumor size (Fig. 3B). Late-relapse class (>6 months) was most strongly linked to LVSI positivity, larger tumor size, and higher stage, supported by ARID1A loss, G3 endometrioid histology, and host factors such as higher BMI/ASA, leukocytosis, and lower hemoglobin.